. 2010 Oct 19;5(10):e13482. doi: 10.1371/journal.pone.0013482

Table 4. Numbers (%) of shared and unique MLVA9-UTRECHT types (MTs) in the four groups of clinical sources compared to the numbers of expected values based on 100.000 permutations (median, range and 95% confidence interval (CI)) when assuming random distribution of types.

			MTs shared (percentage of total MTs) [95% CI]
		Unique	CF	ICU-I	ICU-2	HA	CA
Source			group I	group IIa	group IIb	group III	group IV
CF	Observed	64 (89%)		6 (8%)^a	2 (3%) ^a	0 ^a	0 ^a
	Expected	58 [50–66]		18 [13]–[23]	13 [8]–[18]	8 [4]–[12]	4 [1]–[7]
ICU-1	Observed	72 (88%)	6 (7%) ^a		3 (4%) ^a	0 ^a	0 ^a
	Expected	74 [66–82]	18 [12]–[23]		15 [10]–[20]	9 [5]–[13]	5 [2]–[8]
ICU-2	Observed	58 (92%) ^b	2 (3%) ^a	3 (5%) ^a		0 ^a	0 ^a
	Expected	46 [38–53]	13 [8]–[18]	15 [10]–[20]		7 [3]–[11]	3 [1]–[7]
HA	Observed	30 (91%) ^b	0 ^a	0 ^a	0 ^a		3 (9%)
	Expected	23 [17]–[28]	8 [4]–[12]	9 [5]–[13]	7 [3]–[11]		2 [0–5]
CA	Observed	14 (82%)	0 ^a	0 ^a	0 ^a	3 (18%)
	Expected	10 [6]–[14]	4 [1]–[7]	5 [2]–[8]	3 [1]–[7]	2 [0–5]

CF: cystic fibrosis patients, ICU: intensive care unit patients, HA: non-CF, non-ICU patients with hospital acquired P. aeruginosa, CA: non-CF, non-ICU patients with community acquired P. aeruginosa.

: value lower than expected within 95% CI range, i.e. less overlap of types between sources than in the case of random distribution of types.

: more unique genotypes per source than expected, i.e. high level of source-specificity rather than random distribution.